Answers are grounded in this paper and cite their sources.
This guideline update addresses two clinical questions: (1) What are the defining features of patients with a malignancy who are appropriate candidates for ESA treatment? (2) For patients who are appropriate candidates for treatment with ESAs, what are the optimal approaches to ESA therapy?
No takes yet. Share an insight, caveat, or question.
Rizzo et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: